Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors

The disclosure relates to a substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compound of formula (I) and pharmaceutically acceptable salts thereof in which the variables R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of type III receptor tyr...

Full description

Saved in:
Bibliographic Details
Main Authors MARESKA DAVID A, RAST BRYSON, BOYS MARK LAURENCE, NEWHOUSE BRAD, TOPALOV GEORGE T, ZHAO QIAN, DELISLE ROBERT KIRK, RIZZI JAMES P, HICKEN ERIK JAMES, KENNEDY APRIL L, MUNSON MARK C, RODRIGUEZ MARTHA E, MARMSATER FREDRIK P
Format Patent
LanguageEnglish
Published 24.04.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure relates to a substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compound of formula (I) and pharmaceutically acceptable salts thereof in which the variables R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of type III receptor tyrosine kinases cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Bibliography:Application Number: NZ20110613235